KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $3.0 million.

  • Halozyme Therapeutics' Capital Expenditures rose 99.74% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 16.06%. This contributed to the annual value of $10.7 million for FY2024, which is 30.06% down from last year.
  • Halozyme Therapeutics' Capital Expenditures amounted to $3.0 million in Q3 2025, which was up 93.86% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Capital Expenditures peaked at $11.4 million during Q1 2023, and registered a low of -$1.6 million during Q2 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $2.6 million (2023), whereas its average is $2.9 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 2,281.65% in 2022, then slumped by 267.67% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Capital Expenditures (Quarterly) stood at $158,000 in 2021, then skyrocketed by 2,281.65% to $3.8 million in 2022, then tumbled by 31.01% to $2.6 million in 2023, then grew by 17.57% to $3.1 million in 2024, then spiked by 99.74% to $3.0 million in 2025.
  • Its Capital Expenditures was $3.0 million in Q3 2025, compared to $1.6 million in Q2 2025 and $950,000 in Q1 2025.